188698-46-6

Upstream product

• 220377-99-1 5-(1-trityl-1H-imidazol-4-yl)pentan-1-ol 
• 887276-81-5 5-(1H-imidazol-4-yl)pentanoic acid ethyl ester 
• 887276-80-4 5-[4-(toluene-4-sulfonyl)-4,5-dihydrooxazol-5-yl]pentanoic acid methyl ester 
• 502-44-3 hexahydro-2H-oxepin-2-one 
• 6654-36-0 methyl 6-oxohexanoate 
• 4547-43-7 methyl 6-hydroxycaproate 
• 76-83-5 trityl chloride 
• 102676-68-6 ethyl 5-<1-(triphenylmethyl)-1H-imidazol-4-yl>-1-pentanoate 

Downstream Products

• 887277-03-4 cycloheptyl-[5-(1-trityl-1H-imidazol-4-yl)pentyl]amine 
• 887277-04-5 (4-chlorobenzyl)-[5-(1-trityl-1H-imidazol-4-yl)pentyl]amine 
• 887277-01-2 tert-butyl-[5-(1-trityl-1H-imidazol-4-yl)pentyl]amine 
• 887276-99-5 butyl-[5-(1-trityl-1H-imidazol-4-yl)pentyl]amine 
• 887277-02-3 cyclopentyl-[5-(1-trityl-1H-imidazol-4-yl)pentyl]amine 
• 887277-00-1 isobutyl-[5-(1-trityl-1H-imidazol-4-yl)pentyl]amine 
• 900520-12-9 1-[5-(1-trityl-1H-imidazol-4-yl)pentyl]azepane 
• 887276-97-3 ethyl-[5-(1-trityl-1H-imidazol-4-yl)pentyl]amine 
• 900519-96-2 1-[5-(1-trityl-1H-imidazol-4-yl)pentyl]piperidine 
• 887277-06-7 4-(5-pyrrolidin-1-ylpentyl)-1-trityl-1H-imidazole 
• 220378-02-9 tert-butyl (1-((((4-chlorobenzyl)amino)sulfonyl)methyl)-5-(1-(triphenylmethyl) imidazol-4-yl)pentyl) carbonate 

Relevant academic research and scientific papers

A chemical switch for the modulation of the functional activity of higher homologues of histamine on the human histamine H3 receptor: Effect of various substitutions at the primary amino function

In an effort to establish the structural requirements for agonism, neutral antagonism, and inverse agonism at the human histamine H3 receptor (H3R) we have prepared a series of higher homologues of histamine in which the terminal nitrogen of the side chain has been either mono- or disubstituted with several aliphatic, alicyclic, and aromatic moieties or incorporated in cyclic systems. The novel ligands have been pharmacologically investigated in vitro for their affinities on the human H3R and H4R subtypes by radioligand displacement experiments and for their intrinsic H3R activities via a CRE-mediated β-galactosidase reporter gene assay. Subtle changes of the substitution pattern at the side chain nitrogen alter enormously the pharmacological activity of the ligands, resulting in a series of compounds with a wide spectrum of pharmacological activities. Among the several neutral H3R antagonists identified within this series, compounds 2b and 2h display an H3R affinity in the low nanomolar concentration range (pKi values of 8.1 and 8.4, respectively). A very potent and selective H3R agonist (11, pEC 50 = 8.9, α = 0.94) and a very potent, though not highly selective, H3R inverse agonist (2k, pIC50 = 8.9, α = -0.97) have been identified as well.

Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists

The present invention discloses novel substituted imidazole compounds which have H3 receptor antagonist activity or dual histamine-H1 and H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, congestion, inflammatory and CNS-related diseases and others.

1H-4(5)-substituted imidazole derivatives, their preparation and their use as histamine H3 receptor ligands

A compound of the formula wherein R2is an optionally substituted Czto Cgalkylene or alkylene chain; R3is C2to C15optionally substituted hydrocarbyl; X is a bond or —NR4—, wherein

Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists

The present invention discloses novel substituted imidazole compounds which have H3 receptor antagonist or dual histamine-H1 and H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, nasal congestion, inflammatory and CNS-related diseases and others.